1. Introduction
===============

Circular RNA (circRNA) is a common class of non-coding RNAs produced by back splicing, which is an unconventional splicing event and are characterized as having no 5′ end cap structures or 3′ end poly-adenylation tails ([@b1-ijo-57-01-0021]). Although Sanger *et al* ([@b2-ijo-57-01-0021]) discovered this special type of RNA molecule in 1976, scientists generally believed that it was a product of incorrect splicing and were generally neglected since. That was not until 2013, when Hansen *et al* ([@b3-ijo-57-01-0021]) and Memczak *et al* ([@b4-ijo-57-01-0021]) reported that circRNA served an endogenous role as a microRNA (miRNA) sponge, that gradually changed the perception of researchers. In recent years, with continuous advancements in sequencing technology, an increasing number of circRNAs have been discovered and subsequently studied. Accumulating evidence have suggested that circRNA serves a significant role in the progression of a number of diseases, including Alzheimer\'s disease, cardiovascular disease, diabetes and cancer ([@b3-ijo-57-01-0021]-[@b6-ijo-57-01-0021]). Since circRNA is highly conserved and is stably expressed in various tissues and bodily fluids, it can be applied to predict disease and evaluate the effect of diagnosis and treatment ([@b7-ijo-57-01-0021]). However, the emerging role of circRNA as a biomarker in cancer is becoming particularly prominent.

Digestive system malignancies account for a large proportion of all cancer cases. According to the 2018 Global Cancer Statistics Report released by the World Health Organization, colorectal, gastric, hepatocellular and esophageal cancers were ranked amongst the top 10 in terms of morbidity ([@b8-ijo-57-01-0021]), whilst colorectal, gastric, hepatocellular, esophageal and pancreatic cancers were ranked amongst the top 10 in terms of mortality ([@b8-ijo-57-01-0021]). In addition, colorectal and stomach cancer are ranked amongst the top five in terms of both morbidity and mortality ([@b8-ijo-57-01-0021]). These data suggested that digestive system malignancies have become a significant threat to global health. In recent decades, diagnosis and treatment of tumors of the digestive system have been markedly improved, where several novel strategies have been developed. However, since patients are frequently diagnosed at an advanced stage, the survival rate of patients with digestive system malignancies remain unsatisfactory.

In the present review, the biogenesis, function and role of circRNA in the development of tumors of the digestive system were summarized, where the possibility and emerging role of circRNA as a tumor marker in the digestive system was explored, providing a referencing point for the study of digestive system malignancies.

2. Biogenesis and function of circRNA
=====================================

Biogenesis of circRNA
---------------------

CircRNA is a non-coding RNA that is produced by two possible models of loop generation previously proposed by Jeck *et al* ([@b9-ijo-57-01-0021]): i) Intron-pairing-driven circularization; and ii) lariat-driven circularization, both of which are widely accepted. Intron-pairing-driven circularization occurs as a result of complementary base pairing between different introns in the sequence, bringing adjacent exons to close proximity, following which the spliceosome cut away the adjacent exons and paired introns to form the circRNA. Lariat-driven circularization relies on the covalent interaction between the splice acceptor and donor, resulting in a circRNA containing the exon lariat ([@b9-ijo-57-01-0021]). Intron circRNA is another subtype of circRNA discovered in recent years ([@b10-ijo-57-01-0021]). The 11-nucleotide C-rich element and 7-nucleotide G-rich element in the parent gene of the intron circRNA combine to form a circular structure which are then spliced by the spliceosome ([@b10-ijo-57-01-0021]). The spliceosome mechanism serves a significant role in the biogenesis of circRNA, which depends on trans-acting factors and cis-regulatory elements ([@b11-ijo-57-01-0021]). Zhang *et al* ([@b12-ijo-57-01-0021]) used four thiopurines to label newly generated RNA to reveal that low levels of circRNA may be a by-product of incomplete pre-RNA splicing, whilst the transcription of RNA polymerase II (pol II) occurred simultaneously with the formation of circRNA, suggesting that rapid extension of the strand may promote the reverse splicing of complementary paired sequences. In addition, the activity of pol II is strictly controlled by cis-regulatory elements ([@b12-ijo-57-01-0021]). A number of circRNAs can be detected after pre-mRNA transcription is complete, suggesting that the biogenic process of circRNA may be post-transcriptional ([@b13-ijo-57-01-0021]). In addition to pre-RNA and pol II, the biogenesis of circRNA is also regulated by a variety of proteins, enzymes, intron sequences and active elements. A previous study showed that RNA-binding proteins can also serve as regulators of circRNA production, which is a particularly prevalent mechanism observed during epithelial-mesenchymal transition (EMT) in tumors ([@b14-ijo-57-01-0021]). The RNA helicase DExH-box helicase 9 (DHX9) specifically recognizes the reverse repeat Alu element, which is involved in the regulation of RNA post-transcriptional splicing ([@b15-ijo-57-01-0021]). Alu elements are a class of functional sequences that are widely found in primates and are closely associated with the biogenesis of circRNAs ([@b15-ijo-57-01-0021]). The expression levels of DHX9 affects the formation of splicing products, the deletion of which has been found to increase circRNA biogenesis of ([@b15-ijo-57-01-0021]). In addition, exon circularization is dynamic process that is regulated by neighboring introns, where individual and flanking introns compete to regulate the formation of circRNA through base pairing ([@b16-ijo-57-01-0021]). Modifications to the mRNA have been previously demonstrated to regulate transcription, alternative splicing, formation of advanced structures, translation and stability. Tang *et al* ([@b17-ijo-57-01-0021]) found that N^6^-methyladenosine (m6A) modification can promote the generation of circRNA carrying open reading frames in mouse male germ cells. In addition, the level of other circRNAs in tissues can also adversely affect the biogenesis of circRNA ([@b18-ijo-57-01-0021]).

Function of circRNA
-------------------

CircRNA can be classified into exon circRNA, exon-intron circRNA and intron circRNA, according to their origins ([@b19-ijo-57-01-0021],[@b20-ijo-57-01-0021]). Exon circRNA is generally more commonly observed in eukaryotes ([@b19-ijo-57-01-0021]). Compared with corresponding linear RNA of the same sequence, circRNA is more stable and less susceptible to degradation by RNase R ([@b21-ijo-57-01-0021]), which is one of the main factors for circRNA being considered as a potential biomarker.

CircRNA has a multitude of reported functions ([Fig. 1](#f1-ijo-57-01-0021){ref-type="fig"}), the most studied of which is its property as an endogenous competitive RNA to sponge miRNA ([@b22-ijo-57-01-0021]). miR-7 is a widely studied miRNA that has been reported to participate in cell proliferation, differentiation, migration, invasion and a number of signaling pathways in various types of malignancies, including lung, breast and thyroid cancer ([@b23-ijo-57-01-0021]-[@b25-ijo-57-01-0021]). Hollensen *et al* ([@b26-ijo-57-01-0021]) previously demonstrated that cerebellar degeneration-related autoantigen 1, antisense can (ciRS7 or CDR1AS) act as an negative upstream regulator of miR-7, downregulating miR-7 expression in cells. In recent years, an increasing number of studies have shown miRNA sponging to be the most common function of circRNA. In addition to sponging miRNA, complex interactions between circRNA and proteins have been observed in regulating biological processes. CircRNA can also act as a protein sponge to directly regulate the expression of functional proteins ([@b27-ijo-57-01-0021]). Du *et al* ([@b28-ijo-57-01-0021]) found that circular RNA-forkhead box O3 blocked cell cycle progression by forming a complex with p21 and cyclin dependent kinase (Cdk)2. By contrast, certain circular RNAs have been demonstrated to act synergistically with specific proteins in response to extracellular stimuli ([@b29-ijo-57-01-0021]). Li *et al* ([@b29-ijo-57-01-0021]) found that the synergy between circRNA and the immune factor interleukin enhancer binding factor 3 promoted cellular responses to viral infections. A small number of circRNAs have also been documented to encode genes that can be translated into proteins directly involved in the regulation of physiological functions ([@b30-ijo-57-01-0021]). Circ-ZNF609 binds ribosomes via an internal ribosome entry site and translates into ZNF609 to regulate the proliferation of myoblasts ([@b31-ijo-57-01-0021]). Yang *et al* ([@b30-ijo-57-01-0021]) reported in 2017 that m6A drives the initiation of circRNA translation in human cells. CircRNA has also been shown to regulate the splicing of pre-RNA and the function of the parental gene ([@b10-ijo-57-01-0021],[@b16-ijo-57-01-0021]). This is mainly due to the role of some circRNAs located in the nucleus. For example, the circRNA ciankrd52 has been reported to interact with pol II to promote parental ankyrin repeat domain 52 pre-mRNA transcription ([@b10-ijo-57-01-0021]). In summary, circRNA has a variety of biological functions, though this field of research remains incomplete ([@b10-ijo-57-01-0021]).

3. CircRNA in digestive system malignancies
===========================================

As an important subtype of non-coding RNA, circRNA has received considerable attention in cancer research in recent decades, where an increasing number of studies have shown that circRNA may serve significant roles in a multiple types of digestive system malignancies. By sponging miRNA, circRNA can regulate the expression of target proteins, in turn affecting the pathophysiology of tumors of the digestive system ([Fig. 2](#f2-ijo-57-01-0021){ref-type="fig"}). This section describes the differential expression profiles and reported functions of circRNA in various types of digestive system malignancies.

Esophageal and gastric cancer
-----------------------------

Esophageal cancer is a tumor of the upper digestive tract, which ranks 7th and 6th in terms morbidity and mortality among all cancers, respectively ([@b10-ijo-57-01-0021]). By contrast, gastric cancer ranks 5th and 3rd in terms of morbidity and mortality among all cancers, respectively ([@b8-ijo-57-01-0021]). Although a number of advancements have been made in the diagnosis and treatment of esophageal and gastric cancer in recent years, the etiology of these two malignancies remain to be fully elucidated and the survival rates of patients with advanced disease remain poor. The lack of effective early diagnostic indicators is also an important cause for the high mortality rates observed in patients with these two types of malignancies. Accumulating evidence have shown that circRNA serves a pivotal role in the proliferation, invasion, migration, cell cycle progression and drug resistance of esophageal ([Table I](#tI-ijo-57-01-0021){ref-type="table"}) and gastric cancers ([Table II](#tII-ijo-57-01-0021){ref-type="table"}).

Since 2016, the number of studies on the relationship between circRNAs and esophageal cancer has increased gradually. The elevated expression levels of several circRNAs in esophageal cancer has been demonstrated to promote the proliferation of esophageal cancer cells, including circ-discs large homolog 1, circRNA_100876 and hsa_circ_0067934 ([@b32-ijo-57-01-0021]-[@b34-ijo-57-01-0021]). In addition to proliferation, aberrant circRNA expression has also been reported to influence the ability of cancer cells to invade and migrate, which is a crucial cause of tumor metastasis and subsequent mortality. Zhong *et al* ([@b35-ijo-57-01-0021]) found that circ-plasmacytoma variant translocation (circ-PVT1) upregulated the expression of paired box proteins and peroxisome proliferator-activated receptors by sponging miR-4663, resulting in the promotion of esophageal cancer cell proliferation and migration. The elevated expression levels of circ-tetratricopeptide repeat domain 17, circ-fibronectin type III domain containing 3B (circFNDC3B) and hsa_circ_0000337 have also been revealed to be involved in the proliferation and migration of esophageal cancer cells ([@b36-ijo-57-01-0021]-[@b38-ijo-57-01-0021]). Hsa_circ_0006168, circ-protein kinase Cι (circ-PRKCI), c-zinc finger protein 292 (cZNF292), circRAD23B, circ-ubiquitin associated protein 2 (circUBAP2) and hsa_circ_0004370 were all found to be upregulated in esophageal cancer cells and tissues, where they have the reported function of promoting proliferation, invasion and migration ([@b39-ijo-57-01-0021]-[@b44-ijo-57-01-0021]). Mechanistically, hsa_circ_0006168, circ-PRKCI, cZNF292, circRAD23B regulate the PI3K/AKT/mTOR signaling pathway by sponging miR-100, miR-3680-3p, miR-206 and miR-5095, respectively; whilst circUBAP2 and hsa_circ_0004370 regulate Rab10 and LIM And SH3 protein 1 by sponging miRNA-422a and miR-1294, respectively ([@b39-ijo-57-01-0021]-[@b44-ijo-57-01-0021]). miR-7 is a widely studied miRNA, the expression of which has been previously found to be reduced as a result of competition from ciRS7 in esophageal cancer, leading to the activation of NF-κB signaling, causing changes to the immune micro-environment to potentiate tumorigenesis ([@b45-ijo-57-01-0021]). In addition to proliferation, invasion and migration, evidence also exists demonstrating the role of circRNA in tumor sensitivity to radiotherapy. He *et al* ([@b46-ijo-57-01-0021]) previously found that the down-regulation of circ-vaccinia-related kinase 1 (circVRK1) in patients with esophageal cancer was associated with a lower survival rates, whilst the overexpression of circVRK1 could effectively inhibit EMT and resistance to radiotherapy in esophageal cancer cells.

Similar to esophageal cancer, research on the association between circRNA and gastric cancer has been gradually increasing since 2017. In 2017, studies discovered that circRNA_100269, circRNA_La ribonucleoprotein 4, hsa_circ_0000705, hsa_circ_0001895, hsa_circ_00001649, hsa_circ_0000745 and hsa_circ_0000190 are all significantly downregulated in gastric cancer, which were found to be closely associated with the increased cell proliferation, differentiation, subcellular localization, stage, Borrmann type and invasion ([@b47-ijo-57-01-0021]-[@b53-ijo-57-01-0021]). By contrast, circ-PVT1 was demonstrated to serve as a proliferative factor regulating downstream gene expression by sponging miR-125 in gastric cancer ([@b54-ijo-57-01-0021]). miRNA sponging remains to be the predominant mechanism through which circRNA promotes the proliferation, invasion and migration of gastric cancer cells. By sponging miR-509-3-5p, circ-myeloid/lymphoid or mixed-lineage leukemia has been found to be regulated by the expression of GINS4, which binds to and activates Rac1/cell division cycle to promote cell growth and metastasis *in vivo* and *in vitro*, whilst inhibiting apoptosis ([@b55-ijo-57-01-0021]). Circ-nuclear receptor interacting protein 1, circ-cactin, circ-neurofibromatosis type 1 along with 37 other circRNAs have been previously revealed to regulate the expression of downstream target genes in gastric cancer through miRNA sponging to promote the proliferation and invasion of gastric cancer ([Table II](#tII-ijo-57-01-0021){ref-type="table"}) ([@b56-ijo-57-01-0021]-[@b95-ijo-57-01-0021]). Disorder in fat metabolism is the main cause of cachexia in patients with advanced gastric cancer and systemic inflammation ([@b96-ijo-57-01-0021]). CiRS-133 is a plasma exosomal circRNA that has been found to be significantly upregulated in gastric cancer ([@b96-ijo-57-01-0021]). Zhang *et al* ([@b96-ijo-57-01-0021]) found that it can activate PR/SET domain 16 by inhibiting miR-133, causing the browning of white adipose tissues in patients with gastric cancer. Other circRNAs can also affect the invasion and metastasis of gastric cancer by regulating EMT. The increased expression of circFNDC3B and the reduced expression of circSMAD7 and circ-hippocampus abundant transcript 1 (circHIAT1) in gastric cancer has been found to promote EMT in gastric cancer and induce distant metastasis, which is the primary cause of poor prognosis in patients with advanced gastric cancer ([@b97-ijo-57-01-0021]-[@b99-ijo-57-01-0021]). Hsa_circ_0081143 is another circRNA that is highly expressed in gastric cancer, which is positively associated with lymph node metastasis and TNM staging in advanced gastric cancer ([@b100-ijo-57-01-0021]), the silencing of which can inhibit the development of gastric cancer and enhance the sensitivity of gastric cancer cells to chemotherapeutic agents such as cisplatin ([@b100-ijo-57-01-0021]). Similarly, circAKT3 and circ-fibronectin 1 were found to enhance cisplatin resistance by sponging miR-198 and miR-182-5p, respectively ([@b101-ijo-57-01-0021],[@b102-ijo-57-01-0021]).

Pancreatic cancer
-----------------

Pancreatic cancer is a common tumor of the digestive system. Although the rates of morbidity associated with pancreatic cancer is not as high as other types of digestive system malignancies, including gastric, esophageal, colorectal and hepatocellular cancers, its mortality rate ranks among the highest ([@b8-ijo-57-01-0021]). Pancreatic cancer is mainly divided into two subtypes: Pancreatic ductal adenocarcinoma and pancreatic squamous cell carcinoma, both of which have a poor prognosis, with a 5-year survival rate of \<10% ([@b103-ijo-57-01-0021]). Identifying specific biomarkers and therapeutic targets is important for improving the survival rates of patients with pancreatic cancer.

Interestingly, the majority of circRNAs associated with pancreatic cancer that have been discovered are found to be upregulated ([Table III](#tIII-ijo-57-01-0021){ref-type="table"}). CircRNAs, including hsa_circRNA_0007334, circ-Ras homolog family member T1, hsa_circ_0006215, circ-zinc finger MYM-type containing 2, circ-disintegrin and metalloproteinase domain-containing protein (ADAM) 9 and ciRS-7, compete with miRNAs to promote pancreatic cancer proliferation and inhibit apoptosis ([@b104-ijo-57-01-0021]-[@b109-ijo-57-01-0021]). Other circRNAs can regulate endothelial monolayer permeability, thereby promoting the invasion and migration of pancreatic cancer cells. Circ-low density lipoprotein receptor class a domain containing 3 promotes lymphatic and venous metastasis by sponging miR-137-3p, whilst circ-isoleucyl-tRNA synthetase enhances endothelial monolayer permeability by sponging miR-122 ([@b110-ijo-57-01-0021],[@b111-ijo-57-01-0021]). Abnormalities in the immune microenvironment are common changes observed in advanced pancreatic cancer. Circ_0000977 has been previously found to increase the expression of hypoxia-inducible factor 1 and ADAM10 by competitively binding to miR-153, where circ_0000977 silencing can significantly enhance the cytotoxic effects of natural killer cells on pancreatic cancer ([@b112-ijo-57-01-0021]). Drug resistance is another important underlying cause of poor prognosis in patients with advanced pancreatic cancer. Liu *et al* ([@b113-ijo-57-01-0021]) previously found that knocking down circ-homeodomain interacting protein kinase 3 expression can effectively improve the sensitivity of pancreatic cancer to gemcitabine. In general, there have been a number of studies on the relationship between pancreatic cancer and circRNA, where the role of circRNA in the development of pancreatic cancer require further exploration.

Hepatocellular carcinoma
------------------------

As of 2018, liver cancer ranks 6th in terms of prevalence and 4th in terms of mortality rates among other cancers ([@b8-ijo-57-01-0021]). Liver cancer can be divided into three main subtypes: Hepatocellular carcinoma, bile duct carcinoma and mixed carcinoma by cell type, of which hepatocellular carcinoma is the most frequently observed. Viral hepatitis B (HBV) is one of the main causes of liver cancer in China whereas alcoholic fatty liver disease is the main cause in the Western world ([@b114-ijo-57-01-0021]). Hepatocellular carcinoma as a result of both HBV infection and excessive alcohol consumption are associated with high rates of morbidity and mortality ([@b8-ijo-57-01-0021]). Due to the lack of symptoms in the early developmental stage of hepatocellular carcinoma, many are not diagnosed until advanced stages of the disease ([@b115-ijo-57-01-0021]). Studying the molecular mechanism of circRNA in hepatocellular carcinoma is of great importance for the early diagnosis and treatment of this disease.

In 2016, Yu *et al* ([@b116-ijo-57-01-0021]) found that circ-cerebellar degeneration related protein 1; antisense served as a cancer promotor by binding to miR-7 and upregulating the expression of cyclin E1 and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit d, promoting the proliferation and metastasis of hepatocellular carcinoma. Studies into the role of circRNA in hepatocellular carcinoma has since increased annually. A total of four studies were published the following year, which reported that circRNA serves as an endogenous competitor by regulating the expression of downstream target genes by sponging miRNA to promote hepatocellular carcinoma proliferation, invasion, migration and differentiation, whilst inhibiting apoptosis. This suggests that circRNA can be applied as a biomarker for hepatocellular carcinoma ([Table IV](#tIV-ijo-57-01-0021){ref-type="table"}) ([@b117-ijo-57-01-0021]-[@b120-ijo-57-01-0021]). The number of studies on circRNA in relation to hepatocellular carcinoma increased to 16 in 2018, where it was revealed that in addition to sponging miRNA, circRNA can also participate in the progression of hepatocel-lular carcinoma by directly binding to proteins to regulate their function ([Table IV](#tIV-ijo-57-01-0021){ref-type="table"}) ([@b121-ijo-57-01-0021]-[@b136-ijo-57-01-0021]). For example, circ-cullin 2 was previously demonstrated to promote epithelial-mesenchymal transition by combining vimentin under the regulation of Twist1 in hepatocellular carcinoma ([@b130-ijo-57-01-0021]).

The association between circRNA and cancer, especially that of hepatocellular carcinoma, has become a popular topic of research over the last 2 years. In early 2020, a total of 56 related research articles reporting the relationship between circRNA and hepatocellular carcinoma have been published, which is higher than the number recorded in previous years ([Table IV](#tIV-ijo-57-01-0021){ref-type="table"}) ([@b137-ijo-57-01-0021]-[@b192-ijo-57-01-0021]). The expression of several circRNAs has been reported to be dysregulated in hepatocellular carcinoma, which compete with miRNAs to regulate the expression of downstream target proteins and affect the proliferation, invasion and migration of hepatocellular carcinoma. Some of these circRNAs include hsa_circ_0101432, circ-PVT1, circ-tripartite motif containing 33-12, circRNA-104718, circ-SET domain containing 3, actin histidine methyltransferase, has_circ_0078710, hsa_circ_0064428, circHIAT1, circ-adducin3, hsa_circ_0001649, circ-ADAM metallopeptidase with thrombospondin type 1 motif 14, circ_0008450, hsa_circRNA_103809, circ-homer scaffold protein 1, hsa_circ_0003645, circ-SMG1.72, hsa_circ_0091581, hsa\_ circ_0000092, hsa_circ_0056836, circ-TCF4.85, circ-protein arginine methyltransferase 5 (circPRMT5), circ_0001955, circ-pecanex 1, circRNA-5692, circ-ATP binding cassette subfamily B member 10 and circ-ArfGAP with SH3 domain, ankyrin repeat and PH Domain 1 ([@b137-ijo-57-01-0021],[@b138-ijo-57-01-0021],[@b140-ijo-57-01-0021],[@b145-ijo-57-01-0021],[@b147-ijo-57-01-0021]-[@b150-ijo-57-01-0021], [@b155-ijo-57-01-0021]-[@b157-ijo-57-01-0021],[@b163-ijo-57-01-0021],[@b166-ijo-57-01-0021],[@b176-ijo-57-01-0021]-[@b180-ijo-57-01-0021],[@b183-ijo-57-01-0021]-[@b185-ijo-57-01-0021],[@b187-ijo-57-01-0021],[@b189-ijo-57-01-0021]-[@b192-ijo-57-01-0021]). Previous studies have demonstrated that circRNA in exosomes can regulate the development of hepatocellular carcinoma by deubiquitylation. Circ-leptin receptor, circ-matrix metallopeptidase 2 and hsa_circ_0051443 are common exosomal circRNAs found in hepatocellular carcinoma ([@b142-ijo-57-01-0021],[@b181-ijo-57-01-0021],[@b186-ijo-57-01-0021]). Hypoxia is a principal characteristic of the tumor microenvironment that is considered to be an important factor affecting sensitivity to radiotherapy and chemotherapy ([@b146-ijo-57-01-0021]). Yang *et al* ([@b146-ijo-57-01-0021]) previously found that knocking down cZNF292 expression can inhibit angiogenesis, cell proliferation and resistance to radiotherapy in hepatocellular carcinoma, which may be due to the hypoxic environment induced by cZNF292. Similar to cZNF292, the dysregulation of circRNA_101505, circRNA_104797 and circ_0003418 expression in hepatocellular carcinoma has been demonstrated to increase the resistance of hepatocytes to sorafenib and cisplatin, which is considered to be one of the main underlying causes of poor prognosis in patients with advanced hepatocellular carcinoma ([@b162-ijo-57-01-0021],[@b168-ijo-57-01-0021],[@b174-ijo-57-01-0021]). CircRNA can also directly bind to protein components of important signaling pathways, thereby affecting the physiological behavior of hepatocellular carcinoma. The expression of hsa_circ_0079929 and circ-insulin-like growth factor 1 receptor in hepatocellular carcinoma was demonstrated to be significantly reduced, which induced cell cycle arrest and inhibited apoptosis through the PI3K/AKT/mTOR signal transduction pathway ([@b139-ijo-57-01-0021],[@b170-ijo-57-01-0021]). Circ-BTB domain and CNC homolog 1 was found to be highly expressed in hepatocellular carcinoma, which binds to the embryonic lethal, abnormal vision, drosophila, homolog-like 1 protein and p27 to regulate cell cycle progression and promotes the growth of tumor cells ([@b182-ijo-57-01-0021]). Ma *et al* ([@b161-ijo-57-01-0021]) previously found that circARSP91 enhance innate immune monitoring by enhancing NK cell cytotoxicity and its downregulation in hepatocellular carcinoma promotes immune escape of hepatocellular cancer cells.

In conclusion, circRNA serves a significant role in proliferation, invasion, migration, differentiation, apoptosis, cell cycle and sensitivity to chemotherapy in hepatocellular carcinoma. Future research should focus on identifying specific and sensitive circRNAs that can serve as biomarkers for the early diagnosis and effective treatment of hepatocellular carcinoma, to improve the survival rate of patients with hepatocellular carcinoma.

Gallbladder cancer
------------------

Compared with hepatocellular carcinoma, although the rates of morbidity associated with gallbladder cancer is not as high, the rates of mortality are high where its prognosis poor, due to the highly invasive properties which is frequently diagnosed during the advanced stages of the disease ([@b193-ijo-57-01-0021]). Studies have found that circRNA promotes the proliferation of gallbladder cancer cells through miRNA sponging and direct binding to proteins. As a miRNA sponge, circ-forkhead box protein P1 regulates the expression of pyruvate kinase L/R by sponging miR-370, enhancing the Warburg effect and promoting the proliferation and invasion of gallbladder cancer cells ([@b194-ijo-57-01-0021]). In addition, circ-homeodomain interacting protein kinase 3 has been previously found to increase the expression of Rho-associated coiled-coil containing protein kinase 1-CDK6 by sponging miR-124, promoting the proliferation of gallbladder cancer cells ([@b195-ijo-57-01-0021]). Circ-Erb-B2 binds to the circErb-B2 receptor tyrosine kinase 2 located in the nucleus, which regulates proliferation-associated 2G4-dependent ribosomal DNA transcription and promotes the proliferation of gallbladder cancer ([@b196-ijo-57-01-0021]). In conclusion, research on the mechanism of circRNA involvement in the occurrence and development of gallbladder cancer remains limited ([Table V](#tV-ijo-57-01-0021){ref-type="table"}) and several important issues have yet to be explained. Therefore, there remains room for exploration in this particular field.

Colorectal cancer
-----------------

Colorectal cancer ranks 3rd and 2nd worldwide in terms of morbidity and mortality, respectively, among other types of cancers. ([@b8-ijo-57-01-0021]). Advancements in colonoscopy have facilitated the detection and treatment of precancerous colorectal polyps. However, the mortality and risk associated with colorectal cancer have changed little since 1997 ([@b197-ijo-57-01-0021]). At present, there is an urgent need in identifying novel tumor biomarkers and targeted treatment strategies to improve the early diagnosis and survival rate of patients with colorectal cancer.

Studies into the relationship between colorectal cancer and circRNA preceded those of other digestive system malignancies. In 2015, a study on 31 clinical samples of colorectal cancer found that the elevated expression of hsa_circ_001988 in colorectal cancer is closely associated with the differentiation and infiltration of tumor cells ([@b198-ijo-57-01-0021]). In 2016, circRNA_001569 and hsa_circ_0000069 were found to be highly expressed in patients with colorectal cancer ([@b199-ijo-57-01-0021],[@b200-ijo-57-01-0021]). CircRNA_001569 was demonstrated to regulate the expression of Bcl-2-associated athanogene 4, transcription factor E2F5 and formin like 2 by adsorbing miR-145, though the mechanism mediated by hsa_circ_0000069 remain unknown ([@b199-ijo-57-01-0021],[@b200-ijo-57-01-0021]). In 2017, it was found that the expression of circRNA0003906, circ-BTG3-associated nuclear protein and hsa_circ_0020397 were dysregulated in colorectal cancer ([@b201-ijo-57-01-0021]-[@b203-ijo-57-01-0021]). A total of 10 studies reporting that circRNA regulated the development of colorectal cancer were published in 2018 ([Table VI](#tVI-ijo-57-01-0021){ref-type="table"}) ([@b204-ijo-57-01-0021]-[@b213-ijo-57-01-0021]), which rose to 17 in 2019 and 9 related articles have already been published in the first 2 months of 2020 ([Table VI](#tVI-ijo-57-01-0021){ref-type="table"}) ([@b214-ijo-57-01-0021]-[@b239-ijo-57-01-0021]). Over the last 5 years, the number of studies into the role of circRNA in colorectal cancer has been increasing annually. Most aberrantly expressed circRNAs in colorectal cancer exert their function by adsorbing miRNAs, regulating proteins associated with proliferation, invasion and metastasis, thereby promoting the progression of colorectal cancer. Particular circRNAs of interest include hsa_circ_0136666, circCBL.11, hsa_circRNA_102958, circ-vesicle-associated membrane protein-associated protein A, circ-formin 2, circ_0021977, circ_0026344, circ-integrin subunit-α7, has_circ_0055625, circ-calmodulin regulated spectrin associated protein 1, hsa_circ_0007142, circ-HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1, circ-chaperonin containing TCP1 subunit 3, circ_0000218, hsa_circ_0001178, circPRMT5 and hsa_circ_0004277 ([@b215-ijo-57-01-0021]- [@b220-ijo-57-01-0021],[@b223-ijo-57-01-0021],[@b226-ijo-57-01-0021],[@b227-ijo-57-01-0021],[@b229-ijo-57-01-0021]-[@b234-ijo-57-01-0021],[@b236-ijo-57-01-0021],[@b238-ijo-57-01-0021]). CircRNAs have been reported to serve either a synergistic or antagonistic role by directly binding to downstream target proteins to regulate various aspects of colorectal cancer pathophysiology. Circ-catenin b1 (circ-CTNNB1) mainly exists in the nucleus and directly binds to DEAD-box helicase 3/yin and yang 1, resulting in b-catenin activation and promoting the growth and metastasis of colorectal cancer ([@b225-ijo-57-01-0021]). CircRNA_104916, circ-zinc finger protein 609 and circ-protein tyrosine kinase 2 have been previously demonstrated to function in a similar manner to circ-CTNNB1 ([@b221-ijo-57-01-0021],[@b228-ijo-57-01-0021],[@b237-ijo-57-01-0021]). Exosome circRNA has been a topic of particular research interest in recent years, as it is believed that circRNA may regulate tumor development. Using nanoparticle tracking analysis and transmission electron microscopy, Pan *et al* ([@b222-ijo-57-01-0021]) verified the exosomes in the peripheral blood of patients with colorectal cancer. Hsa_circ_0004771, ciRS-122 and circ-ATP binding cassette subfamily C Member 1 were found to be significantly increased in these exosomes, suggesting their possible application as a suitable biomarker for this disease ([@b222-ijo-57-01-0021],[@b235-ijo-57-01-0021],[@b239-ijo-57-01-0021]).

Gastrointestinal stromal tumor
------------------------------

A gastrointestinal stromal tumor is a non-epithelial type of tumor that can occur in the esophagus, stomach, small intestine, colorectum and abdominal cavity that can cause a variety of symptoms, including pain, bleeding and abdominal discomfort ([@b240-ijo-57-01-0021]). Surgical resection is currently the most common treatment method ([@b240-ijo-57-01-0021]). In a recent study, Jia *et al* ([@b241-ijo-57-01-0021]) used a selective binding complementary competitive endogenous RNA array to analyze gastrointestinal stromal tumors, which found circ_0084097, circ_0069765 and circ_0079471 to be aberrantly expressed in gastrointestinal stromal tumors. Although further study suggested these circRNAs to serve a regulatory role by sponging mir-144-3p, mir-142-5-p and mir-485-3p ([@b241-ijo-57-01-0021]), there is no experimental data on the mechanism of circRNA involved in the development of gastrointestinal stromal tumors. It remains unclear if circRNA can be applied as a biomarker and therapeutic target for the diagnosis of gastrointestinal stromal tumors at present.

4. Non-coding RNAs in digestive system malignancies
===================================================

Non-coding RNA is comprised of a large family of different subtypes of RNA molecules. In addition to circRNA, it also includes miRNA, long non-coding RNA (lncRNA), piwi-interacting RNA, transfer RNA, ribosomal RNA and small interfering RNA. Over the past decade, numerous studies have demonstrated that non-coding RNAs can exert regulatory effects. They serve an irreplaceable role in transcription, post-transcriptional modification, protein remodeling and cell signal transduction ([@b242-ijo-57-01-0021]). Supporting this, non-coding RNA dysfunction has been documented to be associated with the occurrence and progression of various chronic diseases and tumors ([@b242-ijo-57-01-0021]).

miRNA is a family of single-stranded, non-coding RNA that are typically 21-25 nucleotides in length and negatively regulates \>60% of coding genes ([@b243-ijo-57-01-0021]). Most miRNAs contain a 2-7 nucleotide seed sequence at the 3′untranslated region (3′-UTR) end, which can conservatively bind to a variety of target protein-coding genes to inhibit target mRNA translation ([@b243-ijo-57-01-0021]). The function of miRNA itself is under negative regulation by circRNA- or lncRNA-mediated sponging ([@b243-ijo-57-01-0021]). In a previous study, miR-7 was found to inhibit osteosar-coma cell proliferation and migration, but circRNA-CDR1as promotes osteosarcoma growth by sponging miR-7 ([@b244-ijo-57-01-0021]) Similar cancer-promoting effects as a result of reduced miR-7 expression have also been reported in gastric cancer, colorectal cancer, pancreatic cancer and hepatocellular carcinoma ([@b109-ijo-57-01-0021],[@b206-ijo-57-01-0021],[@b245-ijo-57-01-0021],[@b246-ijo-57-01-0021]). However, it should be noted that not all miRNAs have a seed sequence at the 3′UTR end. In addition to directly inhibiting mRNA translation, a number of miRNAs can also participate in pre-transcriptional regulation by binding to the argonaute-2 protein in the nucleus ([@b247-ijo-57-01-0021]). However, this phenomenon is yet to be observed in tumors of digestive system.

LncRNA is a type of non-coding RNA that are \>200 nucleotides in length, which has been previously shown to serve a significant role in maintaining the tumor microenvironment and the progression of various digestive system malignancies ([@b248-ijo-57-01-0021]). Similar to circRNA, many lncRNAs also have the ability to sponge miRNAs. Yuan *et al* ([@b248-ijo-57-01-0021]) found that the lncRNA SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily C member 2 upregulates transmembrane serine protease 2 by binding to miR-551b-3p, promoting the proliferation and invasion of gastric cancer. LncRNA can also directly interact with double-stranded RNA to regulate the activity of some proteins ([@b249-ijo-57-01-0021]). A previous study has found that LINC00665 can activate and enhance the expression of protein kinase R by protecting it from ubiq-uitin-dependent degradation, in turn upregulating the NF-κB signaling pathway and the widespread expression of inflammatory factors, resulting in changes to the microenvironment and the occurrence of hepatocellular carcinoma ([@b249-ijo-57-01-0021]).

In short, non-coding RNA forms a complex network of interactions in the body. where dysfunctions in any one of the nodes will significantly impact the entire non-coding RNA network, resulting in the development of diseases. The occurrence and procession of digestive system malignancies are closely associated with the aberrant expression of these non-coding RNAs. CircRNA is an important part of the non-coding RNA family, where its function in tumors has garnered attention in recent years. The present study reviewed the research status of circRNA in seven types of tumors in the digestive system, where the potential mechanism underlying circRNA function in their respective malignancies were discussed in detail and the possibility of using circRNA as a diagnostic and prognostic marker for tumors in the digestive system was demonstrated. However, this article is associated with limitations, since it did not discuss in detail the role of circRNAs in cellular and signal transduction pathways. CircRNA has a complex intracellular mechanism of action, which is regulated by a variety of transcriptional regulatory factors and can also affect downstream biological functions by direct interaction with miRNAs and proteins. In addition, circRNA can exert biological functions in the nucleus, cytoplasm or through exosomes secreted into bodily fluids. The associated in-depth mechanism in digestive system malignancies remain to be fully elucidated and require further investigation in future studies.

5. Conclusions and perspectives
===============================

The present review briefly explored the biogenesis and function of circRNA and reviewed in detail the current status of circRNA research in various types of digestive system malignancies. CircRNA is a class of endogenous non-coding RNA that is evolutionarily conserved, the expression of which was found to be dysregulated in a variety of digestive system tumors. In digestive system malignancies, the majority of circRNAs serve an endogenous competitive role through miRNA sponging, whilst a selective number of circRNAs can directly bind to proteins either as sponges or synergistic factors to regulate tumor growth, invasion and migration, in turn influencing patient prognosis. Compared with traditional linear RNA and other families of RNA molecules, including long-chain non-coding RNA and miRNA, circRNA is widely expressed in various tissues, cells and bodily fluids, where its expression is stable, increasing their potential as biomarkers and targets for therapy. With continuous advancements in experimental technology and continuing research, it is hoped that novel functions and modes of action mediated by circRNA will be discovered and clarified in the future. With the joint efforts of researchers and clinicians, the pathogenesis of various malignant tumors of the digestive system will be elucidated, so that patients will have an increased chance of survival.
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![Function of circRNA. CircRNA has a variety of biological functions, including the regulation of pre-mRNA splicing and the function of parent genes, miRNA sponging, interactions with proteins and protein translation. CircRNA, circular RNA; miRNA, microRNA.](IJO-57-01-0021-g00){#f1-ijo-57-01-0021}

![CircRNA serves as a miRNA sponge in tumors of the digestive system. After the parental gene is spliced into a loop through a complex process in the nucleus, the mature circRNA enters the cytoplasm and sequesters miRNAs, reducing their downstream effects, in turn regulating the expression of downstream target proteins and affecting tumor proliferation, invasion and migration. CircRNA, circular RNA; miRNA, microRNA.](IJO-57-01-0021-g01){#f2-ijo-57-01-0021}

###### 

Circular RNAs in esophageal cancer.

  CircRNA name       Status          Function                                           Sponge target   Signaling pathway   (Refs.)                     Publication date
  ------------------ --------------- -------------------------------------------------- --------------- ------------------- --------------------------- ------------------
  circUBAP2          Upregulated     Promote proliferation, migration and invasion      miRNA-422a      Rab10               ^([@b42-ijo-57-01-0021])^   2020
  circPVT1           Upregulated     Proliferative factor, promote migration            miR-4663        Paxs, PPARs         ^([@b35-ijo-57-01-0021])^   2019
  circ-TTC17         Upregulated     Promote proliferation and migration                                                    ^([@b36-ijo-57-01-0021])^   2019
  hsa_circ_0000337   Upregulated     Promote growth, migration, and invasion            miR-670-5p                          ^([@b38-ijo-57-01-0021])^   2019
  hsa_circ_0006168   Upregulated     Promote proliferation, migration and invasion      miR-100         mTOR                ^([@b39-ijo-57-01-0021])^   2019
  circ-PRKCI         Upregulated     Stimulate migration and proliferation              miR-3680-3p     AKT3                ^([@b40-ijo-57-01-0021])^   2019
  cZNF292            Upregulated     Promote growth, migration, and invasion            miR-206         AMPK, PI3K/AKT      ^([@b41-ijo-57-01-0021])^   2020
  ciRS-7             Upregulated     Trigger migration and invasion                     miR-7           KLF4, NF-κB         ^([@b45-ijo-57-01-0021])^   2019
  circVRK1           Downregulated   Regulate progression and radio resistance          miR-624-3p      PTEN/PI3K/AKT       ^([@b46-ijo-57-01-0021])^   2019
  circRAD23B         Upregulated     Facilitates proliferation and invasion             miR-5095        PARP2, AKT2         ^([@b43-ijo-57-01-0021])^   2019
  hsa_circ_0004370   Upregulated     Regulate proliferation, apoptosis, and migration   miR-1294        LASP1               ^([@b44-ijo-57-01-0021])^   2019
  circ-DLG1          Upregulated     Promote proliferation                                                                  ^([@b32-ijo-57-01-0021])^   2018
  circRNA_100876     Upregulated     Promote proliferation, migration, invasion                                             ^([@b33-ijo-57-01-0021])^   2018
  circFNDC3B         Upregulated     Regulate proliferation, apoptosis, and migration                                       ^([@b37-ijo-57-01-0021])^   2018
  hsa_circ_0067934   Upregulated     Promote proliferation                                                                  ^([@b34-ijo-57-01-0021])^   2016

###### 

Circular RNAs in gastric cancer.

  CircRNA name        Dysregulation   Function                                           Sponge target    Signaling pathway     (Refs.)                      Publication date
  ------------------- --------------- -------------------------------------------------- ---------------- --------------------- ---------------------------- ------------------
  circHIPK3           Upregulated     Promote Progression And Migration                  miR-107          BDNF                  ^([@b66-ijo-57-01-0021])^    2020
  circRBM33           Upregulated     Promote Progression, Migration And Invasion        miR-149          IL-6                  ^([@b67-ijo-57-01-0021])^    2020
  circ_0006282        Upregulated     Promote Progression And Metastasis                 miR-155          FBXO22                ^([@b68-ijo-57-01-0021])^    2020
  circUBA1            Upregulated     Promote Proliferation And Metastasis               miR-375          TEAD4                 ^([@b69-ijo-57-01-0021])^    2020
  hsa_circ_0000467    Upregulated     Promote Progression And Invasion,                  miR-326-3p       Cyclin D1             ^([@b70-ijo-57-01-0021])^    2020
  hsa_circ_0010882    Upregulated     Regulate proliferation, migration and invasion                      PI3K/Akt/mTOR         ^([@b71-ijo-57-01-0021])^    2020
  circSMAD7           Downregulated   Promote Migration, Invasion And Emt                                                       ^([@b98-ijo-57-01-0021])^    2020
  circ-CEP85L         Downregulated   Suppress Proliferation And Invasion                miR-942-5p       NFKBIA                ^([@b83-ijo-57-01-0021])^    2020
  circATXN7           Downregulated   Regulate Proliferation, Apoptosis And Invasion     miR-4319         ENTPD4                ^([@b84-ijo-57-01-0021])^    2020
  circHIAT1           Downregulated   Inhibit Proliferation And Emt                      miR-21           p53, p21              ^([@b99-ijo-57-01-0021])^    2020
  circMAN2B2          Dpregulated     Promote Growth And Migration                       miR-145          PI3K/AKT, JNK         ^([@b72-ijo-57-01-0021])^    2020
  circRHOBTB3         Downregulated   Inhibit Proliferation                              miR-654-3p       p21                   ^([@b85-ijo-57-01-0021])^    2020
  circRNA_104433      Upregulated     Regulate Proliferation, Apoptosis And Cell Cycle   miR-497-5p       Cell cycle proteins   ^([@b73-ijo-57-01-0021])^    2020
  circ-NOTCH1         Upregulated     Promote Progression, Migration And Invasion        miR-449c-5p      MYC/NOTCH1            ^([@b74-ijo-57-01-0021])^    2020
  circFN1             Upregulated     Enhance Cisplatin Resistance                       miR-182-5p                             ^([@b102-ijo-57-01-0021])^   2020
  circMLLT10          Upregulated     Promote Growth And Metastasis                      miR-5093-5p      GINS4/Rac1/CDC42      ^([@b55-ijo-57-01-0021])^    2019
  circNRIP1           Upregulated     Promote Progression                                miR-149-5p       AKT1/mTOR             ^([@b56-ijo-57-01-0021])^    2019
  circCACTIN          Upregulated     Promote Progression                                miR-331-3p       TGFBR1                ^([@b57-ijo-57-01-0021])^    2019
  ciRS-133            Upregulated     Exosome, Promote White Adipose Browning            miR-133                                ^([@b96-ijo-57-01-0021])^    2019
  hsa_circ_0067997    Upregulated     Promote Progression                                miR-515-5p       XIAP                  ^([@b60-ijo-57-01-0021])^    2019
  hsa_circ_0081143    Upregulated     Promote Cisplatin Resistance                       miR-646          CDK6                  ^([@b100-ijo-57-01-0021])^   2019
  circ-DCAF6          Upregulated     Regulate Invasion, Metastasis And Tnm Stages       miR-1231                               ^([@b80-ijo-57-01-0021])^    2019
  hsa_circ_0000144    Upregulated     Promote Tumor Growth                                                                      ^([@b61-ijo-57-01-0021])^    2019
  circNF1             Upregulated     Promote The Progression                            miR-16           MAP7, AKT3            ^([@b58-ijo-57-01-0021])^    2019
  circRNA_001569      Upregulated     Promote The Progression                            miR-145          NR4A2                 ^([@b59-ijo-57-01-0021])^    2019
  circPSMC3           Downregulated   Suppress The Proliferation And Metastasis          miR-296-5p       PTEN                  ^([@b87-ijo-57-01-0021])^    2019
  circPDSS1           Upregulated     Promote The Progression                            miR-186-5p       NEK2                  ^([@b62-ijo-57-01-0021])^    2019
  hsa_circ_0006848    Downregulated   Negatively correlated with poor differentiation    hsa_miR-329-5p   RPL6                  ^([@b75-ijo-57-01-0021])^    2019
  hsa_circ_0001368    Downregulated   Suppress The Progression                           miR-6506-5p      FOXO3                 ^([@b76-ijo-57-01-0021])^    2019
  circYAP1            Downregulated   Inhibit proliferation and invasion                 miR-367-5p       p27 Kip1              ^([@b77-ijo-57-01-0021])^    2019
  hsa_circ_0000592    Upregulated     Regulate apoptosis, proliferation and metastasis   miR-139-3p                             ^([@b63-ijo-57-01-0021])^    2019
  hsa_circ_006100     Upregulated     Promote Cell Growth And Metastasis                 miR-195          GPRC5A                ^([@b64-ijo-57-01-0021])^    2019
  circSMARCA5         Downregulated   Inhibits gastric cancer progression                miR-346          FBXL2                 ^([@b78-ijo-57-01-0021])^    2019
  circAKT3            Upregulated     Enhance Cisplatin Resistance                       miR-198          PIK3R1                ^([@b101-ijo-57-01-0021])^   2019
  hsa_circ_0008035    Upregulated     Promote Progression                                miR-375          YBX1                  ^([@b65-ijo-57-01-0021])^    2019
  circFNDC3B          Upregulated     Promotes Migration And Invasion                    IGF2BP3          E-cadherin, CD44      ^([@b97-ijo-57-01-0021])^    2019
  circLMTK2           Downregulated   Suppress viability and mobility                                                           ^([@b82-ijo-57-01-0021])^    2019
  circFAT1(e2)        Downregulated   Inhibit progression                                miR-548g         YBX1                  ^([@b79-ijo-57-01-0021])^    2019
  circ-DONSON         Upregulated     Facilitates growth and invasion                    NURF             SOX4                  ^([@b81-ijo-57-01-0021])^    2019
  circHECTD1          Upregulated     Facilitates glutaminolysis, promote progression    miR-1256         β-catenin/c-Myc       ^([@b86-ijo-57-01-0021])^    2019
  circRNA_0023642     Upregulated     Promotes migration and invasion                    EMT                                    ^([@b88-ijo-57-01-0021])^    2018
  hsa_circ_0074362    Downregulated   Associate with lymphatic metastasis                                                       ^([@b89-ijo-57-01-0021])^    2018
  circ_0027599        Downregulated   Suppress progression                               miR-101-3p       PHLDA1                ^([@b90-ijo-57-01-0021])^    2018
  hsa_circ_0003159    Downregulated   Inhibit metastasis                                                                        ^([@b91-ijo-57-01-0021])^    2018
  circPVRL3           Downregulated   Suppress the proliferation and migration           9 miRNAs         PTB, EIF4A3           ^([@b92-ijo-57-01-0021])^    2018
  circ-SFMBT2         Upregulated     Promotes the proliferation                         miR-182-5p       CREB1                 ^([@b93-ijo-57-01-0021])^    2018
  circ_0066444        Upregulated     Promote proliferation, invasion and migration                                             ^([@b94-ijo-57-01-0021])^    2018
  circ_0009910        Upregulated     Regulate proliferation, migration and invasion                                            ^([@b95-ijo-57-01-0021])^    2018
  circRNA_100269      Downregulated   Suppress growth                                    miR-630                                ^([@b47-ijo-57-01-0021])^    2017
  circLARP4           Downregulated   Inhibit proliferation and invasion                 miR-424-5p       LATS1                 ^([@b48-ijo-57-01-0021])^    2017
  hsa_circ_0000705    Downregulated   Borrmann type, pathologic diagnosis                                                       ^([@b49-ijo-57-01-0021])^    2017
  hsa_circ_0001895    Downregulated   Regulate cell differentiation, Borrmann type                                              ^([@b50-ijo-57-01-0021])^    2017
  hsa_circ_00001649   Downregulated   Regulate cell differentiation, Borrmann type                                              ^([@b51-ijo-57-01-0021])^    2017
  hsa_circ_0000745    Downregulated   Regulate tumor differentiation                                                            ^([@b52-ijo-57-01-0021])^    2017
  hsa_circ_0000190    Downregulated   Regulate metastasis, TNM stage                                                            ^([@b53-ijo-57-01-0021])^    2017
  circPVT1            Upregulated     Proliferative factor                               miR-125                                ^([@b54-ijo-57-01-0021])^    2017

###### 

Circular RNAs in pancreatic cancer.

  CircRNA name       Dysregulation   Function                                          Sponge target         Signaling pathway   (Refs.)                      Publication date
  ------------------ --------------- ------------------------------------------------- --------------------- ------------------- ---------------------------- ------------------
  circHIPK3          Upregulated     Promote gemcitabine resistance                    miR-330-5p            RASSF1              ^([@b113-ijo-57-01-0021])^   2020
  hsa_circ_0007334   Upregulated     Promote proliferation and invasion                miR-144-3p, miR-577   MMP7, COL1A1        ^([@b104-ijo-57-01-0021])^   2019
  circRHOT1          Upregulated     Promote proliferation and invasion                miR-26b, miR-125a                         ^([@b105-ijo-57-01-0021])^   2019
  circADAM9          Upregulated     Promote proliferation, migration and invasion     miR-217               PRSS3/ERK/VEGF      ^([@b108-ijo-57-01-0021])^   2019
  ciRS-7             Upregulated     Promote the proliferation and metastasis          miR-7                 EGFR/STAT3          ^([@b109-ijo-57-01-0021])^   2019
  circ_0000977       Upregulated     Regulate NK cell immune activity                  miR-153               HIF1, ADAM10        ^([@b112-ijo-57-01-0021])^   2019
  hsa_circ_0006215   Upregulated     Regulate proliferation and apoptotic              miR-378a-3p           SERPINA4            ^([@b106-ijo-57-01-0021])^   2018
  circZMYM2          Upregulated     Regulate proliferation, invasion, and apoptosis   miR-335-5p            JMJD2C              ^([@b107-ijo-57-01-0021])^   2018
  circ-IARS          Upregulated     Regulate endothelial monolayer permeability       miR-122               F-actin             ^([@b111-ijo-57-01-0021])^   2018
  circ-LDLRAD3       Upregulated     Promote invasion, invasion, and metastasis                                                  ^([@b110-ijo-57-01-0021])^   2017

###### 

Circular RNAs in hepatocellular carcinoma.

  CircRNA name       Dysregulation   Function                                            Sponge target   Signaling pathway   (Refs.)                      Publication date
  ------------------ --------------- --------------------------------------------------- --------------- ------------------- ---------------------------- ------------------
  circBACH1          Upregulated     Promote growth, regulate cell cycle                                 HuR/p27             ^([@b182-ijo-57-01-0021])^   2020
  circ-HOMER1        Upregulated     Regulate the growth and invasion                    miR-1322        CXCL6               ^([@b176-ijo-57-01-0021])^   2020
  hsa_circ_0056836   Upregulated     Promote migration, proliferation and invasion       miR-766-3p      FOSL2               ^([@b183-ijo-57-01-0021])^   2020
  hsa_circ_0051443   Downregulated   Exosome, regulate apoptosis and cell cycle                                              ^([@b186-ijo-57-01-0021])^   2020
  hsa_circ_0000092   Upregulated     Promote proliferation, migration and invasion       miR-338-3p      HN1                 ^([@b180-ijo-57-01-0021])^   2020
  hsa_circ_0003645   Upregulated     Regulate proliferation, apoptosis and invasion      miR-1299        PI3K/mTOR           ^([@b177-ijo-57-01-0021])^   2020
  hsa_circ_0091581   Upregulated     Promote cell proliferation                          miR-526b        c-MYC               ^([@b179-ijo-57-01-0021])^   2020
  circ-PRMT5         Upregulated     Promote proliferation, migration and glycolysis     miR-188-5p      HK2                 ^([@b185-ijo-57-01-0021])^   2020
  circ-TCF4.85       Upregulated     Regulate proliferation, apoptosis and invasion      miR-486-5p      ABCF2               ^([@b184-ijo-57-01-0021])^   2020
  circ_MMP2          Upregulated     Exosome, Promote metastasis                         miR-136-5p      MMP2                ^([@b181-ijo-57-01-0021])^   2020
  circ-SMG1.72       Upregulated     Promote invasion                                    miR-141-3p      Gelsolin            ^([@b178-ijo-57-01-0021])^   2020
  hsa_circ_0101432   Upregulated     Promote growth                                      miR-1258        MAPK1               ^([@b137-ijo-57-01-0021])^   2019
  circPVT1           Upregulated     Promote progression                                 miR-203         HOXD3               ^([@b138-ijo-57-01-0021])^   2019
  hsa_circ_0079929   Downregulated   Inhibit growth                                                      PI3K/AKT/mTOR       ^([@b139-ijo-57-01-0021])^   2019
  circTRIM33-12      Downregulated   Suppress progression                                miR-191         TET1                ^([@b140-ijo-57-01-0021])^   2019
  circ_0008450       Upregulated     Regulate proliferation, apoptosis and invasion      miR-548p                            ^([@b141-ijo-57-01-0021])^   2019
  exo-circ-DB        Upregulated     Promote growth and reduces DNA damage               miR-34a         USP7/Cyclin A2      ^([@b142-ijo-57-01-0021])^   2019
  circRNA_103809     Upregulated     Promote proliferation and migration                 miR-377-3p      FGFR1/ERK           ^([@b143-ijo-57-01-0021])^   2019
  hsa-circ-0046600   Upregulated     Regulate tumor size, TNM stage and invasion         miR-640         HIF-1 alpha         ^([@b144-ijo-57-01-0021])^   2019
  circRNA-104718     Upregulated     Promote progression                                 miR-218-5p      TXNDC5              ^([@b145-ijo-57-01-0021])^   2019
  cZNF292            Upregulated     Regulate proliferation and radio resistance                                             ^([@b146-ijo-57-01-0021])^   2019
  circSETD3          Downregulated   Inhibiting growth                                   miR-421         MAPK14              ^([@b147-ijo-57-01-0021])^   2019
  has_circ_0078710   Unregulated     Promoted proliferation, migration and invasion      miR-31          Cyclin protein      ^([@b148-ijo-57-01-0021])^   2019
  hsa_circ_0064428   Downregulated   Regulate tumor size and metastasis                                                      ^([@b149-ijo-57-01-0021])^   2019
  circHIAT1          Downregulated   Inhibits cell growth                                miR-3171        PTEN                ^([@b150-ijo-57-01-0021])^   2019
  hsa_circ_0000517   Upregulation    Associated with adverse prognosis                                   MAPK, Ras           ^([@b151-ijo-57-01-0021])^   2019
  circRHOT1          Upregulation    Promote progression                                                 NR2F6               ^([@b152-ijo-57-01-0021])^   2019
  circPTGR1          Upregulation    In exosomal, Promote metastasis                     miR449a         MET                 ^([@b153-ijo-57-01-0021])^   2019
  circZFR            Upregulation    Promote progression                                 miR-3619-5p     CTNNB1, Wnt         ^([@b154-ijo-57-01-0021])^   2019
  circ-ADD3          Downregulated   Inhibit metastasis+                                                 CDK1/EZH2           ^([@b155-ijo-57-01-0021])^   2019
  hsa_circ_0001649   Downregulated   Inhibit progression                                 miR-127-5p,                         ^([@b156-ijo-57-01-0021])^   2019
  circADAMTS14       Downregulated   Suppress progression                                micR-572        Calcineurin1        ^([@b157-ijo-57-01-0021])^   2019
  circADAMTS13       Downregulated   Suppress proliferation                              miR-484                             ^([@b158-ijo-57-01-0021])^   2019
  circ_0000267       Upregulation    Promote progression                                 miR-646                             ^([@b159-ijo-57-01-0021])^   2019
  circRNA-10720      Upregulation    Metastasis                                                          Twist1              ^([@b160-ijo-57-01-0021])^   2019
  circARSP91         Downregulated   Increase cell cytotoxicity                                          ULBP1               ^([@b161-ijo-57-01-0021])^   2019
  circRNA_101505     Downregulated   Sensitizes to cisplatin                             miR-103         NOR1                ^([@b162-ijo-57-01-0021])^   2019
  hsa_circ_0008450   Upregulated     Promote proliferation, invasion and migration       miR-214-3p      EZH2                ^([@b163-ijo-57-01-0021])^   2019
  circ-catenin       Upregulated     Promote growth                                                      Wnt                 ^([@b164-ijo-57-01-0021])^   2019
  circMYLK           Upregulated     Promote progression                                 miR-362-3p      Rab23               ^([@b165-ijo-57-01-0021])^   2019
  hsa_circ_103809    Downregulated   Suppress proliferation and invasion                 miR-620                             ^([@b166-ijo-57-01-0021])^   2019
  hsa_circ_0078602   Downregulated   Suppress proliferation                                                                  ^([@b167-ijo-57-01-0021])^   2019
  circRNA_104797     Upregulated     Sorafenib resistance                                                UBQLN1              ^([@b168-ijo-57-01-0021])^   2019
  hsa_circ_0016788   Upregulated     Regulate tumorigenesis                              miR-486         CDK4                ^([@b169-ijo-57-01-0021])^   2019
  circ-IGF1R         Upregulated     Pro-proliferative and anti-apoptotic                                PI3K/AKT            ^([@b170-ijo-57-01-0021])^   2019
  hsa_circ_0002124   Upregulated     Promote proliferation                                               MAPK                ^([@b171-ijo-57-01-0021])^   2019
  circLARP4          Downregulated   Regulate proliferation, cell cycle and senescence   miR-761         RUNX3/p53/p21       ^([@b172-ijo-57-01-0021])^   2019
  circRNAs_100395    Downregulated   Regulate differentiation, microvascular invasion    miR-1228                            ^([@b173-ijo-57-01-0021])^   2019
  circ_0003418       Downregulated   Inhibit genesis and cisplatin chemoresistance                       Wnt/β-Catenin       ^([@b174-ijo-57-01-0021])^   2019
  hsa_circ_101280    Upregulated     Promote proliferation                               miR-375         JAK2                ^([@b175-ijo-57-01-0021])^   2019
  circ_0001955       Upregulated     Promote proliferation                               miR-516a-5p     TRAF6, MAPK11       ^([@b187-ijo-57-01-0021])^   2019
  circ-MALAT1        Upregulated     Promote cancer stem cell self-renewal               miR-6887-3p     PAX5                ^([@b188-ijo-57-01-0021])^   2019
  circPCNX           Upregulated     Promote proliferation                               miR-506                             ^([@b189-ijo-57-01-0021])^   2019
  circRNA-5692       Downregulated   Inhibit proliferation and invasion                  miR-328-5p      DAB2IP              ^([@b190-ijo-57-01-0021])^   2019
  circABCB10         Upregulated     Promote proliferation and invasion                  miR-670-3p      HMG20A              ^([@b191-ijo-57-01-0021])^   2019
  circASAP1          Upregulated     Promote proliferation, migration and invasion       miR-326         MAPK1, CSF-1        ^([@b192-ijo-57-01-0021])^   2019
  circ_0067934       Upregulated     Promote growth and metastasis                       miR-1324        FZD5/Wnt            ^([@b121-ijo-57-01-0021])^   2018
  circC3P1           Downregulated   Suppress growth and metastasis                      miR-4641        PCK1                ^([@b122-ijo-57-01-0021])^   2018
  hsa_circ_0001445   Upregulated     Regulate proliferation and migration                                                    ^([@b123-ijo-57-01-0021])^   2018
  circRNA_104075     Upregulated     Promote progression                                 miR-582-3p      HNF4a, YAP          ^([@b124-ijo-57-01-0021])^   2018
  circSMAD2          Downregulated   Inhibit the epithelial-mesenchymal transition       miR-629                             ^([@b125-ijo-57-01-0021])^   2018
  circSLC3A2         Upregulated     Promote growth and invasion                         miR-490-3p      PPM1F/AKT           ^([@b126-ijo-57-01-0021])^   2018
  hsa_Circ_0091579   Upregulated     Associated with a worse overall survival                                                ^([@b127-ijo-57-01-0021])^   2018
  cSMARCA5           Downregulated   Inhibit growth and metastasis                       miR-181b-5p     TIMP3               ^([@b128-ijo-57-01-0021])^   2018
  hsa_circRBM23      Upregulated     Increase cell viability and also migration          miR-138         Vimentin, CCND3     ^([@b129-ijo-57-01-0021])^   2018
  circCul2           Upregulated     Promote EMT                                                         Twist1, Vimentin    ^([@b130-ijo-57-01-0021])^   2018
  circPTPRM          Upregulated     Promote proliferation and migration                                                     ^([@b131-ijo-57-01-0021])^   2018
  circ_101368        Upregulated     Correlated with poorer prognosis                    miR-200a        HMGB1/RAGE          ^([@b132-ijo-57-01-0021])^   2018
  hsa_circ_0005075   Upregulated     Increase proliferative, migrate and invasive        miR-431                             ^([@b133-ijo-57-01-0021])^   2018
  circ-ZEB1.33       Upregulated     Promote the proliferation                           miR-200a-3p     CDK6                ^([@b134-ijo-57-01-0021])^   2018
  hsa_circ_0128298   Upregulated     A diagnostic factor                                                                     ^([@b135-ijo-57-01-0021])^   2018
  hsa_circ_0103809   Upregulated     Promote and inhibits apoptosis                      miR-490-5p      SOX2                ^([@b136-ijo-57-01-0021])^   2018
  circZKSCAN1        Downregulated   Inhibit growth, migration and invasion                                                  ^([@b117-ijo-57-01-0021])^   2017
  circRNA_000839     Upregulated     Promote the invasion and migration                  miR-200b        RhoA                ^([@b118-ijo-57-01-0021])^   2017
  circRNA-100338     Upregulated     Regulate metastatic progression                     miR-141-3p                          ^([@b119-ijo-57-01-0021])^   2017
  circ\_ 0004018     Downregulated   Regulate tumor diameters, differentiation                                               ^([@b120-ijo-57-01-0021])^   2017
  circCdr1as         Upregulated     Promote proliferation and invasion                  miR-7           CCNE1, PIK3CD       ^([@b116-ijo-57-01-0021])^   2016

###### 

Circular RNAs in gallbladder cancer.

  CircRNA name   Dysregulation   Function                                              Sponge target   Signaling pathway   (Refs.)                      Publication date
  -------------- --------------- ----------------------------------------------------- --------------- ------------------- ---------------------------- ------------------
  circFOXP1      Upregulated     Promote progression and Warburg effect                miR-370         PKLR                ^([@b194-ijo-57-01-0021])^   2019
  circERBB2      Upregulated     Regulate proliferation, ribosomal DNA transcription                                       ^([@b196-ijo-57-01-0021])^   2019
  circHIPK3      Upregulated     Promote growth                                        miR-124         ROCK1-CDK6          ^([@b195-ijo-57-01-0021])^   2018

###### 

Circular RNAs in colorectal cancer.

  CircRNA name       Dysregulation   Function                                         Sponge target   Signaling pathway       (Refs.)                      Publication date
  ------------------ --------------- ------------------------------------------------ --------------- ----------------------- ---------------------------- ------------------
  circ-ABCC1         Upregulated     Exosome, Promote metastasis                                      Wnt/β-catenin pathway   ^([@b239-ijo-57-01-0021])^   2020
  circPTK2           Upregulated     Promote tumor growth, EMT, metastasis                            Vimentin protein        ^([@b237-ijo-57-01-0021])^   2020
  circPRMT5          Upregulated     Promote proliferation                            miR-377         E2F3                    ^([@b236-ijo-57-01-0021])^   2020
  ciRS-122           Upregulated     Exosome, Promote oxaliplatin resistance          miR-122         PKM2                    ^([@b235-ijo-57-01-0021])^   2020
  hsa_circ_0004277   Upregulated     Regulate proliferation and apoptosis             miR-512-5p      PTMA                    ^([@b238-ijo-57-01-0021])^   2020
  hsa_circ_0001178   Upregulated     Promote invasion and metastasis                  miR-382         ZEB1                    ^([@b234-ijo-57-01-0021])^   2020
  circ_0000218       Upregulated     Enhance the proliferation and metastasis         miR-139-3p      RAB1A                   ^([@b233-ijo-57-01-0021])^   2020
  circCCT3           Upregulated     Enhance metastasis                               miR-613         VEGFA, Wnt              ^([@b232-ijo-57-01-0021])^   2020
  circHUWE1          Upregulated     Promote proliferation, migration and invasion    miR-486                                 ^([@b231-ijo-57-01-0021])^   2020
  hsa_circ_0007142   Upregulated     Regulate differentiation and metastasis          miR-103a-2-5p                           ^([@b230-ijo-57-01-0021])^   2019
  circZNF609         Downregulated   Promote apoptosis                                                PCNA, c-Myc, Bax,       ^([@b228-ijo-57-01-0021])^   2019
  has_circ_0055625   Upregulated     Increases colon cancer cell growth               miR-106b-5p     ITGB8                   ^([@b227-ijo-57-01-0021])^   2019
  circ-ITGA7         Downregulated   Suppress proliferation                           miR-3187-3p     ASXL1                   ^([@b226-ijo-57-01-0021])^   2019
  circ-CTNNB1        Upregulated     Promote progression                                              DDX3/YY1/β-Catenin      ^([@b225-ijo-57-01-0021])^   2019
  hsa_circ_0004585   Upregulated     Regulate tumor size and metastasis                                                       ^([@b224-ijo-57-01-0021])^   2019
  circ_0026344       Downregulated   Restrain metastasis and EMT                      miR-183         CCL20, CXCL8            ^([@b223-ijo-57-01-0021])^   2019
  hsa-circ-0004771   Upregulated     Exosome, as a biomarker                                                                  ^([@b222-ijo-57-01-0021])^   2019
  circRNA_104916     Downregulated   Regulate migration, apoptosis and EMT                            LoVo, Caco-2            ^([@b221-ijo-57-01-0021])^   2019
  circ_0021977       Downregulated   Suppress growth, migration and invasion          miR-10b-5p      P21, P53                ^([@b220-ijo-57-01-0021])^   2019
  circVAPA           Upregulated     Promote proliferation, migration, invasion       miR-101                                 ^([@b218-ijo-57-01-0021])^   2019
  circRNA_102958     Upregulated     Promote tumorigenesis                            miR-585         CDC25B                  ^([@b217-ijo-57-01-0021])^   2019
  circCBL.11         Downregulated   Suppress proliferation                           miR-6778-5p     YWHAE                   ^([@b216-ijo-57-01-0021])^   2019
  hsa_circ_0136666   Upregulated     Promote the proliferation and invasion           miR-136         SH2B1                   ^([@b215-ijo-57-01-0021])^   2019
  hsa_circ_0009361   Downregulated   Suppress progression                             miR-582         APC2                    ^([@b214-ijo-57-01-0021])^   2019
  circCAMSAP1        Upregulated     Promote growth                                   miR-328-5p      E2F1                    ^([@b229-ijo-57-01-0021])^   2019
  circFMN2           Upregulated     Promote proliferation                            miR-1182        hTERT                   ^([@b219-ijo-57-01-0021])^   2019
  hsa_circ_0007534   Upregulated     Promote progression, Suppress apoptosis                                                  ^([@b204-ijo-57-01-0021])^   2018
  circHIPK3          Upregulated     Promote growth and metastasis                    miR-7           FAK, IGF1R, EGFR        ^([@b205-ijo-57-01-0021])^   2018
  circ_0026344       Downregulated   Suppress progression                             miRNA-31                                ^([@b206-ijo-57-01-0021])^   2018
  circ-ZNF609        Upregulated     Promote migration                                miR-150         Gli1                    ^([@b207-ijo-57-01-0021])^   2018
  circDDX17          Downregulated   Suppress proliferation, invasion and apoptosis                                           ^([@b208-ijo-57-01-0021])^   2018
  circITGA7          Downregulated   Inhibit growth and metastasis                    miR-370-3p      Ras, ITGA7              ^([@b209-ijo-57-01-0021])^   2018
  hsa_circ_0000523   Downregulated   Suppress proliferation and induce apoptosis      miR-31          Wnt/β-catenin           ^([@b210-ijo-57-01-0021])^   2018
  circRNA-ACAP2      Downregulated   Suppress growth, migration and invasion          miR-21-5p       Tiam1                   ^([@b211-ijo-57-01-0021])^   2018
  circRNA_100290     Upregulated     Promote progression                              miR-516b        FZD4, Wnt/β-catenin     ^([@b212-ijo-57-01-0021])^   2018
  circRNA_103809     Downregulated   Suppress proliferation and migration             miR-532-3p      FOXO4                   ^([@b213-ijo-57-01-0021])^   2018
  circRNA0003906     Downregulated   Regulate metastasis and poor differentiation                                             ^([@b201-ijo-57-01-0021])^   2017
  circular BANP      Upregulated     Promote cell proliferation                                                               ^([@b202-ijo-57-01-0021])^   2017
  hsa_circ_0020397   Upregulated     Promote invasion, inhibit apoptosis              miR-138         TERT, PD-L1             ^([@b203-ijo-57-01-0021])^   2017
  circRNA_001569     Upregulated     Regulate proliferation and invasion              miR-145         E2F5, BAG4, FMNL2. I    ^([@b199-ijo-57-01-0021])^   2016
  hsa_circ_0000069   Upregulated     Promote growth, migration and invasion                                                   ^([@b200-ijo-57-01-0021])^   2016
  hsa_circ_001988    Upregulated     Regulate differentiation and invasion                                                    ^([@b198-ijo-57-01-0021])^   2015

[^1]: Contributed equally
